recombinant hyaluronidase
Pre-clinical- Indications
- Drug delivery
Company intelligence / Profile preview
Genica Biosciences develops novel animal-free recombinant enzymes and diagnostic kits to replace imported or animal-derived products. Their lead product—recombinant hyaluronidase—is ready for clinical trials to support enhanced drug delivery. They are also developing a sustainable recombinant endotoxin kit as an alternative to traditional crab blood-based tests. The company’s focus includes sustainability in biotech manufacturing and supporting the lab-grown meat industry with non-animal derived reagents.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Genica Biosciences.